Cover Image
市場調查報告書

胞漿素原活性化因子抑制劑-1 (內皮層胞漿素原活性化因子抑制劑、SerpinE1、PAI-1) - 開發中產品分析

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358688
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
胞漿素原活性化因子抑制劑-1 (內皮層胞漿素原活性化因子抑制劑、SerpinE1、PAI-1) - 開發中產品分析 Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 63 Pages
簡介

胞漿素原活性化因子抑制劑-1 (PAI-1) ,也稱為內皮層胞漿素原活性化因子抑制劑,是Serpin1遺傳基因編碼的蛋白質。PAI-1上升,是血栓症和動脈粥狀硬化性心血管疾病的危險因素。

本報告提供胞漿素原活性化因子抑制劑-1 (內皮層胞漿素原活性化因子抑制劑、SerpinE1、PAI-1)的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等系統性資訊。

目錄

簡介

概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症

開發中產品的概要

  • 後期階段的產品
  • 初期階段的產品

開發中的產品:各企業

各開發中的產品:各大學/研究機關

治療藥的評估

  • 各單劑/聯合治療
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • D-Pharm Ltd.
  • Jazz Pharmaceuticals Plc

藥物簡介

暫停的計劃

開發中止的產品

最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0439TDB

Summary

Global Markets Direct's, 'Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016', provides in depth analysis on Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted pipeline therapeutics.

The report provides comprehensive information on the Plasminogen (Plasmin or PLG or EC 3.4.21.7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Plasminogen (Plasmin or PLG or EC 3.4.21.7)
  • The report reviews Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Plasminogen (Plasmin or PLG or EC 3.4.21.7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Plasminogen (Plasmin or PLG or EC 3.4.21.7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Plasminogen (Plasmin or PLG or EC 3.4.21.7) Overview
  • Therapeutics Development
    • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Stage of Development
    • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Therapy Area
    • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Indication
  • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Companies
  • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Companies Involved in Therapeutics Development
    • Bayer AG
    • Bharat Biotech International Limited
    • F. Hoffmann-La Roche Ltd.
    • Grifols, S.A.
    • Hyundai Pharmaceutical Co., Ltd.
    • Kedrion S.p.A.
    • Nostrum Pharmaceuticals, LLC
    • Omeros Corporation
    • ProMetic Life Sciences Inc.
  • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Drug Profiles
    • alteplase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-616 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plasminogen (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plasminogen (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plasminogen (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Prourokinase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SMRX-11 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAL-0500018 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THR-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TMS-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tranexamic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTS-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Dormant Projects
  • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Discontinued Products
  • Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Featured News & Press Releases
    • Jun 13, 2016: ProMetic plasminogen granted Fast Track designation by the US FDA
    • May 11, 2016: Positive response in kidney and urinary tract to ProMetic plasminogen treatment in a plasminogen deficient patient under an expanded access protocol in the USA
    • May 10, 2016: Major new global study identifies a safer treatment of acute stroke
    • May 03, 2016: Prometic announces successful treatment of a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA
    • Feb 18, 2016: Clot-busting therapy reduces mortality in deadliest form of stroke
    • Dec 07, 2015: ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case
    • Nov 04, 2015: Prometic'S Plasminogen Drug Successfully Used to Treat Plasminogen Deficient Infant in Critical Condition
    • Aug 10, 2015: Prometic Successfully Completes First Dosing In Plasminogen Deficient Patients
    • Aug 04, 2015: European Commission Grants Orphan Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug
    • Jul 23, 2015: MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke
    • Oct 28, 2014: ProMetic's Plasminogen IND and Clinical Program Cleared by FDA
    • Aug 22, 2014: MHRA To Review Ischemic Stroke Drug
    • Feb 13, 2014: CSIR Developed Clot Specific Streptokinase Enters into Phase-2 Human Clinical Trials
    • Jun 25, 2013: Kedrion Announces Plasminogen clinical study now started on drug for treatment of ligneous conjunctivitis
    • Feb 28, 2013: Mitsubishi Tanabe Pharma And Kyowa Hakko Kirin Receive Japanese Approval For Time-Window Extension Of Thrombolytic Agents GRTPA And Activacin
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Bayer AG, H2 2016
  • Pipeline by Bharat Biotech International Limited, H2 2016
  • Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Pipeline by Grifols, S.A., H2 2016
  • Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Pipeline by Kedrion S.p.A., H2 2016
  • Pipeline by Nostrum Pharmaceuticals, LLC, H2 2016
  • Pipeline by Omeros Corporation, H2 2016
  • Pipeline by ProMetic Life Sciences Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top